RhumbLine Advisers
ZVRA icon

RhumbLine Advisers’s Zevra Therapeutics ZVRA Stock Holding History

RhumbLine Advisers’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
77,137
+9,066
+13% +$101K ﹤0.01% 2254
2026
Q1 		$634K Sell
68,071
-213
-0.3% -$1.92K ﹤0.01% 2459
2025
Q4 		$612K Sell
68,284
-9,205
-12% -$87.1K ﹤0.01% 2552
2025
Q3 		$737K Sell
77,489
-5,732
-7% -$57.5K ﹤0.01% 2431
2025
Q2 		$733K Buy
83,221
+8,636
+12% +$70.1K ﹤0.01% 2412
2025
Q1 		$559K Buy
74,585
+6,532
+10% +$51.9K ﹤0.01% 2502
2024
Q4 		$568K Buy
68,053
+10,573
+18% +$90.3K ﹤0.01% 2599
2024
Q3 		$399K Buy
57,480
+606
+1% +$4.11K ﹤0.01% 2863
2024
Q2 		$279K Buy
56,874
+8,619
+18% +$40.8K ﹤0.01% 3042
2024
Q1 		$280K Buy
48,255
+1,065
+2% +$6.55K ﹤0.01% 3019
2023
Q4 		$309K Buy
47,190
+1,469
+3% +$6.87K ﹤0.01% 2950
2023
Q3 		$220K Buy
45,721
+2,558
+6% +$12.8K ﹤0.01% 3110
2023
Q2 		$220K Buy
+43,163
New +$233K ﹤0.01% 3191
2022
Q2 		– Sell
-32,381
Closed -$163K – 3252
2022
Q1 		$163K Sell
32,381
-850
-3% -$5.41K ﹤0.01% 2800
2021
Q4 		$289K Buy
33,231
+506
+2% +$4.51K ﹤0.01% 2718
2021
Q3 		$305K Buy
32,725
+893
+3% +$9K ﹤0.01% 2759
2021
Q2 		$408K Buy
+31,832
New +$342K ﹤0.01% 2654

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RhumbLine Advisers's ZVRA Position: Q2 2026 in Review

RhumbLine Advisers increased its Zevra Therapeutics (ZVRA) stake by 13% in Q2 2026, buying an estimated $101K and bringing the position to 77,137 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2254.

RhumbLine Advisers first reported a position in ZVRA in Q2 2021 and has held it in 17 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • RhumbLine Advisers held 77,137 shares of Zevra Therapeutics worth $1.11M as of Q2 2026.
  • RhumbLine Advisers bought 9,066 Zevra Therapeutics shares in Q2 2026, an estimated $101K.
  • Zevra Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2254 holding.
  • RhumbLine Advisers first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.